JCB, Volume 10, Number 1, 2003 Editorial Vol.10 No. 1 (2003) Editorial: Creating a competitive European life science sector Jane Fisken   Editorial Vol.10 No. 1 (2003) Financing papers: The role of the European Commission in fostering innovation in the life sciences and biotechnology Waldemar Kütt Life sciences and biotechnology are fundamental to our ability to meet societal, environmental and economic challenges, be it the healthcare needs of a rich but ageing Article Vol.10 No. 1 (2003) Commercial biotechnology in Germany: An overview Siegfried Bialojan The title of Ernst & Young's 2003 Biotechnology Report, 'At the Crossroad', describes the present situation of the German biotechnology industry. This paper discuss Article Vol.10 No. 1 (2003) What will it take to get institutional investors interested in life sciences again? William Brooks With the European biotechnology market nearing a crisis state, companies must try to attract and maintain interest from institutional investors. In this article, a brie Article Vol.10 No. 1 (2003) Consolidation challenges in Europe's life science sector – Making it happen Wolfgang Stoiber Even though the current market environment is tough on biotechnology companies, the number of consolidation transactions in Europe has fallen. Platform specialists have Article Vol.10 No. 1 (2003) Riposte: FDA response to 'Yin, yang and the biopharmaceutical industry' Amy S Rosenberg In his editorial entitled 'Yin, yang, and the biopharmaceutical industry', Henry Miller attributes the three-year decline in biotechnology stocks to two factors: compet Article Vol.10 No. 1 (2003) The Sarbanes–Oxley Act and non-US issuers: Considerations for international companies Megan N Gates The Sarbanes–Oxley Act of 2002 was signed into law by President George W. Bush on 30th July, 2002, in the wake of an unprecedented wave of corporate governance a Article Vol.10 No. 1 (2003) Biotechnology and pharmaceutical R&D and licensing trends: You pays your money and takes your chances Alan Ratliff R&D costs in the biotechnology and pharmaceutical industries continue to rocket, as do royalty rates for the relatively few new drugs and technology that successful Article Vol.10 No. 1 (2003) The impact of pharmacogenetics and pharmacogenomics Klaus Lindpaintner Pharmacogenetics is widely proclaimed as about to revolutionise the face of medicine. In a more realistic assessment, the implementation of molecular genetics and biolo Article Vol.10 No. 1 (2003) A new model to evaluate the market for biotechnology Amanda McMurray There is a clear need for a tool for market analysis of biotechnology markets. There are many well-respected and well-established models for market analysis but none th Article Vol.10 No. 1 (2003) Biotechnology M&A insight: Deals and strategies Alex K Pavlou Biotechnology mergers and acquisitions (Biotech M&A) can help the industry's fully integrated players to increase in size and market value, boost the emerging playe Article Vol.10 No. 1 (2003) Additional on-line material: Pharmacoeconomics and the growth of the biotechnology industry Thomas D Szucs Assuming a constant stream of new biotechnology products in the future, three key issues are likely to influence the growth of the biotechnology industry in an increasi Legal and Regulatory Updates Vol.10 No. 1 (2003) Legal and regulatory update John Wilkinson The Office of Fair Trading (OFT) has recently found Genzyme Limited guilty of abusing its dominant position in the market for the supply of drugs for the treatment of G Legal and Regulatory Updates Vol.10 No. 1 (2003) Financial accounts reports David Citron Antisoma, founded in 1988, specialises in the development of novel anti-cancer drugs. Its strategy is to focus on the middle pre-clinical and clinical development stage Book Review Vol.10 No. 1 (2003) Book Review: Biotech Alliances: Bridging the R&D Gap Nerida Scott Biotech Alliances: Bridging the R&D Gap Stephen Seget Scrip Reports; PJB Publications, Richmond; 181pp